CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
2022年9月12日 - 9:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated oncology therapeutics, today announced that
its collaborator, Bristol Myers Squibb, presented updated Phase 1
results with BMS-986249, a Probody® therapeutic version of
ipilimumab, the anti-CTLA-4 antibody, at the ESMO Congress 2022 in
Paris, France.
“BMS-986249 is a conditionally activated
CTLA-4-targeting antibody that has shown clinical activity in
multiple tumor types, and the safety profile and disease control
rate observed in the updated Phase 1 data for BMS-986249 with and
without nivolumab is promising. BMS-986249 appears to be tolerated
at higher doses than traditional ipilimumab dosing, and we are
encouraged by the report of a complete response in melanoma and a
case study of a partial response in microsatellite-stable
colorectal cancer. This Phase 1 study set the stage for the ongoing
randomized Phase 2 trial of BMS-986249 in melanoma evaluating the
potential differentiation of the Probody from ipilimumab, and we
look forward to results from this study in due course,” said Sean
McCarthy, D.Phil., chief executive officer and chairman of CytomX
Therapeutics.
About CytomX Therapeutics,
Inc.CytomX is a clinical-stage, oncology-focused
biopharmaceutical company dedicated to destroying cancer
differently. By pioneering a novel class of conditionally activated
biologics, powered by its Probody® technology platform, CytomX’s
goal is to transcend the limits of current cancer treatments.
CytomX’s robust and differentiated pipeline comprises seven
therapeutic candidates across multiple treatment modalities. Three
of these candidates are in Phase 2 studies across multiple cancer
types, including CX-2029 and praluzatamab ravtansine. CX-2029 is an
investigational conditionally activated antibody-drug conjugate
(ADC) directed toward CD71, which has demonstrated encouraging
antitumor activity in patients with squamous non-small cell lung
cancer and is being developed in collaboration with AbbVie.
Praluzatamab ravtansine is an investigational conditionally
activated ADC directed toward CD166 and is being studied in
patients with advanced breast cancer. CytomX’s clinical pipeline
also includes cancer immunotherapeutic candidates against validated
targets such as the CTLA-4-targeting Probody therapeutics,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, as
well as CX-904, a conditionally activated T-cell-engaging
bispecific antibody targeting the epidermal growth factor receptor
on tumor cells and the CD3 receptor on T cells, which is partnered
with Amgen. In addition, CytomX has a diverse preclinical portfolio
of wholly-owned assets such as CX-801, an interferon alpha-2b
Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors, and CX-2051, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. CytomX has established
strategic collaborations with multiple leaders in oncology,
including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For
more information about CytomX and how it is working to make
conditionally activated treatments the new standard-of-care in the
fight against cancer, visit www.cytomx.com and follow us on
LinkedIn and Twitter.
Forward-Looking StatementsThis
press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements, including those relating to
the potential benefits, safety and efficacy or progress of CytomX’s
or any of its collaborative partners’ product candidates, including
BMS-986249, praluzatamab ravtansine, CX-2029, BMS-986288,
pacmilimab, CX-904, CX-801, and CX-2051, the potential benefits or
applications of CytomX’s Probody platform technology, CytomX’s
ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing and
planned clinical trials of praluzatamab ravtansine, CX-2029,
BMS-986249, BMS-986288, pacmilimab, and CX-904, and the timing of
the commencement of clinical trials, initial and ongoing data
availability, investigational new drug applications and other
development milestones. Risks and uncertainties that contribute to
the uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the possibility that the results of early
clinical trials for any of our product candidates, including
BMS986249, may not be predictive of future results; the possibility
that CytomX’s clinical trials will not be successful; the
possibility that current preclinical research may not result in
additional product candidates; CytomX’s dependence on the success
of praluzatamab ravtansine, CX-2029, BMS-986249, BMS-986288,
pacmilimab, CX-904, CX-801, and CX-2051; CytomX’s reliance on third
parties for the manufacture of the Company’s product candidates;
possible regulatory developments in the United States and
foreign countries; and the risk that the COVID-19 worldwide
pandemic may continue to negatively impact the business, research
and clinical operations of CytomX or its partners, including the
development of preclinical drug candidates due to delays in and
disruption of research activities and the development of clinical
drug candidates due to delays in or disruption of clinical trials,
including impacts on the enrollment of patients in clinical trials
or other clinical trial disruptions. Additional applicable risks
and uncertainties include those relating to our preclinical
research and development, clinical development, and other risks
identified under the heading "Risk Factors" included in CytomX’s
Quarterly Report on Form 10-Q filed with
the SEC on August 4, 2022. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accountingcogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 9 2024 まで 10 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 10 2023 まで 10 2024